Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
0.3200
+0.0140 (4.58%)
At close: Jun 27, 2025, 4:00 PM
0.3240
+0.0040 (1.25%)
After-hours: Jun 27, 2025, 7:55 PM EDT
Intensity Therapeutics Employees
As of December 31, 2024, Intensity Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,144,571
Market Cap
8.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | 0 | - |
| Dec 31, 2023 | 7 | 1 | 16.67% |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
INTS News
- 16 days ago - Intensity Therapeutics, Inc. Announces Pricing of Public Offering - PRNewsWire
- 16 days ago - Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - PRNewsWire
- 16 days ago - Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - PRNewsWire
- 4 weeks ago - Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - PRNewsWire
- 4 weeks ago - Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon - PRNewsWire
- 6 weeks ago - Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France - PRNewsWire
- 2 months ago - Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PRNewsWire